{"id":"NCT04646109","sponsor":"Afyonkarahisar Health Sciences University","briefTitle":"Ivermectin for Severe COVID-19 Management","officialTitle":"The Effectiveness and Safety of Ivermectin as add-on Therapy in Severe COVID-19 Management","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-05-11","primaryCompletion":"2020-09-02","completion":"2020-09-02","firstPosted":"2020-11-27","resultsPosted":"2021-01-27","lastUpdate":"2021-01-27"},"enrollment":66,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["COVID-19"],"interventions":[{"type":"DRUG","name":"Ivermectin","otherNames":["Hydroxychloroquine, favipiravir and azithromycin"]}],"arms":[{"label":"Control Group","type":"NO_INTERVENTION"},{"label":"Study Group","type":"EXPERIMENTAL"}],"summary":"In this multicenter study; it was aimed to investigate the effectiveness and safety of ivermectin use in the treatment of patients with severe COVID-19 pneumonia that have no mutations which alter ivermectin metabolism and cause side effects.","primaryOutcome":{"measure":"Gender Distribution of the Patients","timeFrame":"At the first day of the study","effectByArm":[{"arm":"Control Group","deltaMin":19,"sd":null},{"arm":"Study Group","deltaMin":21,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":4,"countries":["Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["32109013","32307245","27242902","32533071","32251768"],"seeAlso":["https://covid19.who.int/"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["Nausea and vomiting","Increase in liver function tests"]}}